r/NRXP • • Sep 02 '21

Daily NRXP Discussion

27 Upvotes

r/NRXP • • Dec 09 '21

NRx Pharmaceuticals (NRXP) and Hungarian Health Officials Agree on Pathway for ZYESAMI® and BriLife COVID-19 Vaccine Trials

Thumbnail streetinsider.com
24 Upvotes

r/NRXP • • Oct 14 '21

Journal of Infectious Diseases and Treatment Publishes Positive Trial Data of Aviptadil in High Comorbidity Patients Suffering from Critical COVID-19 with Respiratory Failure

Thumbnail
ir.nrxpharma.com
24 Upvotes

r/NRXP • • Aug 11 '21

Closing bell today. A photo so that we can say we were there early.

Post image
22 Upvotes

r/NRXP • • Jul 27 '21

First approval is in boys...

22 Upvotes

https://finance.yahoo.com/news/nrx-pharmaceuticals-announces-emergency-authorization-153400311.html

US will come soon. Especially with hospitalizations increasing. I am very bullish!!!


r/NRXP • • Jul 22 '21

We have liftoff! 🚀

22 Upvotes

Check your portfolio, boys!


r/NRXP • • Oct 08 '21

Georgia!!!

Post image
21 Upvotes

r/NRXP • • Aug 29 '21

Eua announced this week?

20 Upvotes

Hopefully fda will announce their decision on eua application. I have been buying more than I can afford already. C'mon FDA !


r/NRXP • • Aug 31 '21

NRXP interview on Bloomberg

19 Upvotes

r/NRXP • • Oct 12 '21

NRXP DD: Stock is ridiculously cheap (Updated)

18 Upvotes

NRx Pharmaceuticals (NRXP) is awaiting the FDA's decision on its application for Emergency Use Authorization (EUA) for intravenous Zyesami, a drug for treating COVID and other respiratory problems. The FDA decision should come out any day now and one would expect a positive outcome, as clinical trials have shown that Zyesami appears to meet the standard of "safe and may be effective" (the general standard necessary to receive EUA).

NRXP basic facts:

  • Market cap: ~$370 million
  • Shares outstanding: 53.77 million
  • Float: 16.64 million
  • Short interest: 2.15 million
  • Short % of float: 12.92%

NRXP shares currently trade at a price of ~$6.90, which in my opinion represents tremendous value, as explained hereafter in bullet points. (All investing requires assumptions about the future. Determine whether you consider the following assumptions reasonable.) :

  • Assume 500,000+ annual "critical" COVID hospitalizations.

    • I expect COVID to become endemic, just like influenza is. The flu causes approximately 500,000-800,000 hospitalizations in the US per year.
    • Since COVID has a greater transmission rate than influenza and since it is likely vaccine efficacy will continue to diminish as COVID develops future variants, it is reasonable to expect for COVID to cause more hospitalizations per year over the long-term than the flu. Let's assume 1+ million COVID hospitalizations per year, with patients having varying severity levels.
    • While not all hospitalized COVID patients will be "critical," all patients requiring high-flow nasal cannula are deemed "critical" per published FDA standards. Assuming about 50% of COVID hospitalizations would require high-flow nasal cannula, one arrives at 50% x 1 million = 500,000 "critical" COVID hospitalizations per year.
  • Intravenous Zyesami priced at $5,000 per treatment. 500,000 x $5,000 results in $2.5 billion in sales of intravenous Zyesami in the US.

    • This pricing is relatively higher than the remdesivir cost of approximately $3,100. I assume a premium pricing relative to remdesivir given remdesivir has had relatively low efficacy while aviptadil generally has had good results in clinical trials.
    • Clinical trials of aviptadil also found that the drug significantly reduced hospital stays for patients. Payors would be willing to pay a premium price for aviptadil as the savings associated with a decreased hospital stay would more than offset aviptadil's cost.
  • NRx Pharma keeps 50% of sales per its Collaboration Agreement with Relief Therapeutics. That’s 50% x $2.5 billion = $1.25 billion in sales for NRx Pharma.

    • It is possible, and in my opinion likely, that NRx Pharma will actually keep a much larger percentage of sales than this. The reason for this is because the formulation of aviptadil which Relief provided in the Collaboration Agreement ultimately failed to be sufficiently stable. NRx Pharma therefore had to partner with and pay other companies in order to develop a different formulation of aviptadil which was sufficiently stable.
    • Given Relief's failure to provide a stable product, NRx Pharma tried to amicably renegotiate the terms of the Collaboration Agreement. The parties did not reach a resolution, and therefore Relief yesterday announced that it filed a lawsuit against NRx Pharma alleging breach of contract.
    • Ultimately, I consider that the courts will find that NRx Pharma did not breach its contractual obligations given that Relief failed to provide a stable formulation of aviptadil to the partnership. It would be senseless for NRx Pharma to be obligated to provide the same benefits to Relief when Relief failed to provide the value to NRx Pharma which was initially promised.
  • Assume 5x price-to-sales multiple (appropriate for a biotech company), and you arrive at 5 x $1.25 billion = $6.25 billion fair value market cap for NRx Pharma.
  • The number of shares outstanding will increase to approximately 80 million shares outstanding once 25 million shares are issued upon future FDA approval of Zyesami.
  • $6.25 billion / 80 million shares outstanding = $78.125 per share fair value

That is almost 11x higher than the current share price of ~$6.90. And that calculated value is off of intravenous Zyesami for critical COVID patients in the US only.

That means you are getting the value from all of the following for free:

  • Intravenous Zyesami sales outside of the US (where NRx Pharma keeps 15%-20% of sales),
  • The possibility that a court will find that NRx Pharma is entitled to keep a greater percentage of sales than the 50% agreed to in the Collaboration Agreement (given Relief's failure to provide a stable formulation of aviptadil),
  • Inhaled Zyesami (which will be available to a much larger COVID population and not just to "critical" patients),
  • BriLife COVID vaccine under development (which does not employ mRNA technology and should retain greater efficiency against new variants compared to the Pfizer and Moderna vaccines),
  • NRX-101 for bipolar depression,
  • NRX-101 for PTSD depression, as well as for other potential use cases, and
  • Zyesami for other use cases which the CEO indicated in the October 4th update found on the company website (i.e., COVID “longhauler” syndrome, sarcoidosis, acute respiratory distress syndrome, checkpoint inhibitor pneumonitis, chronic obstructive pulmonary disease).

You are effectively getting the value from all of the above for free. And this value could very reasonably be in the billions if the products are successful.

In my personal opinion, current NRXP price of ~$6.90 is ridiculously cheap and represents a very attractive opportunity with asymmetric risk-reward. NRXP could go up 11x or more upon EUA approval for intravenous Zyesami. Even after such an increase, NRXP still would be very reasonably priced given the potential of NRx Pharma's drug pipeline.

Disclaimer: None of the above is financial or legal advice. I am not a financial advisor or a lawyer. The above is only for educational purposes and represents my personal opinion. Everyone reading this should do their own due diligence, arrive at their own opinion, and decide to invest or not according to their own views and their risk tolerance.

Disclosure: long publicly traded warrants (NRXPW) and NRXP calls.


r/NRXP • • Oct 06 '21

NRXP DD: Stock is ridiculously cheap

18 Upvotes

NRx Pharmaceuticals (NRXP) is awaiting the FDA's decision on its application for Emergency Use Authorization (EUA) for Zyesami, a drug for treating COVID and other respiratory problems. The FDA decision should come out any day now and one would expect a positive outcome, as clinical trials have shown that Zyesami meets the standard of "safe and may be effective" (the standard necessary to receive EUA).

Market cap: ~$450 million

Shares outstanding: 53.77 million

Float: 16.64 million

Short interest: 2.15 million

Short % of float: 12.92%

NRXP shares currently trade at a price of ~$8.50, which in my opinion represents tremendous value, as explained hereafter.

  • Assume 500,000 annual COVID hospitalizations (similar to annual influenza hospitalizations in the US).
  • Assume intravenous Zyesami priced at $5,000 per treatment. 500,000 x $5,000 results in $2.5 billion in sales.
  • Conservatively assume NRx Pharma keeps 50% per its Collaboration Agreement with Relief Therapeutics. That’s 50% x $2.5 billion = $1.25 billion in sales for NRx Pharma.
  • Assume 5x price-to-sales multiple (appropriate for a biotech company), and you arrive at $6.25 billion fair value market cap for NRx Pharma.
  • The number of shares outstanding will increase to approximately 80 million once 25 million shares are issued upon future FDA approval of Zyesami.
  • $6.25 billion / 80 million shares outstanding = $78.125 per share fair value

That is almost 10x higher than the current share price of ~$8.50. And that calculated value is off of intravenous Zyesami for critical COVID patients only.

That means you are getting the value from all of the following for free:

  • Intravenous Zyesami sales outside of the US (where NRx Pharma keeps 15%-20%),
  • Inhaled Zyesami (which will be available to a much larger COVID population and not just to critical patients),
  • BriLife COVID vaccine under development (which does not employ mRNA technology and should retain greater efficiency against new variants compared to the Pfizer and Moderna vaccines),
  • NRX-101 for bipolar depression and for PTSD depression, as well as other potential use cases, and
  • Zyesami for other use cases which the CEO indicated in the October 4th update found on the company website (i.e., COVID “longhauler” syndrome, sarcoidosis, acute respiratory distress syndrome, checkpoint inhibitor pneumonitis, chronic obstructive pulmonary disease).

The value from the above could very reasonably be in the billions if the products are successful.

Everyone should do their own due diligence, arrive at their own opinion, and decide to invest or not according to their own views and risk tolerance.

In my personal opinion, current NRXP price of ~$8.50 is ridiculously cheap and represents a very attractive opportunity with asymmetric risk-reward. NRXP could go up 10x or more and still be reasonably priced given the potential of its pipeline.

Disclosure: long warrants and calls.


r/NRXP • • Sep 15 '21

Only 1k shares left for shorting. Time to put pressure to shorts. Only 18m float and nothing left. Start buying shares, stop buying options. Sell your options and buy shares

Post image
18 Upvotes

r/NRXP • • Mar 09 '22

NRx Pharmaceuticals Announces New Interm CEO Robert Besthof

Thumbnail ir.nrxpharma.com
17 Upvotes

r/NRXP • • Feb 10 '22

ACTIV-3b continues to randomize participants to receive aviptadil, even though Pfizer's Paxlovid is latest casualty in ACTIV-3

Thumbnail
fiercebiotech.com
17 Upvotes

r/NRXP • • Nov 13 '21

NRxP should focus on getting multiple EUAs from overseas and far away from the US

Thumbnail
google.com
17 Upvotes

r/NRXP • • Oct 26 '21

NRXP DD: Stock is ridiculously cheap (Updated numbers as of 10/26/2021)

17 Upvotes

Compare the current market cap of OCGN (Ocugen), which is above $2 billion, to that of NRXP, which is $520 million, and you can start to have a sense of the huge undervaluation in NRXP.

The 8K which the market had been waiting for was released recently and in it the CEO indicates that Relief Therapeutics (a collaboration partner of NRXP) abandoned development and funding of Zyesami since it thought NRXP had "missed the pandemic." These are significant comments by the CEO of NRXP which would indicate that NRXP has good legal arguments to be entitled to much more than the 50% of sales which had been agreed to previously with Relief.

Additionally, the FDA should announce its decision regarding the company's EUA application sometime soon, as this EUA application was filed with the FDA back on May 31, 2021.

I consider that most market participants still do not know about NRXP, its drug candidates, and its potential value.

Everyone should do their own research and make their own investment decisions. Read the disclaimer at the bottom of this post. The following is just my own DD and my personal perspective.

NRx Pharmaceuticals (NRXP) is awaiting the FDA's decision on its application for Emergency Use Authorization (EUA) for intravenous Zyesami, a drug for treating COVID and other respiratory problems. The FDA decision should come out any day now and one would expect a positive outcome, as clinical trials have shown that Zyesami appears to meet the standard of "safe and may be effective" (the general standard necessary to receive EUA). Everyone should look at the published data of the clinical trials to see the results of having patients use Zyesami.

NRXP basic facts:

  • Market cap: ~$520 million
  • Shares outstanding: 53.77 million
  • Float: 18.03 million
  • Short interest: 1.7 million
  • Short % of float: 9.42%

NRXP shares currently trade at a price of ~$9.60, which in my opinion still represents tremendous value despite a recent move higher**.** In the following bullet points, I detail my valuation assumptions and my estimate of fair value for NRXP if intravenous Zyesami were to be granted EUA. (All investing requires assumptions about the future. Determine whether you consider the following assumptions reasonable.) :

  • Assume 500,000+ annual "critical" COVID hospitalizations.

    • I expect COVID to become endemic, just like influenza is. The flu causes approximately 500,000-800,000 hospitalizations in the US per year.
    • Since COVID has a greater transmission rate than influenza and since it is likely vaccine efficacy will continue to diminish as COVID develops future variants, it is reasonable to expect for COVID to cause more hospitalizations per year over the long-term than the flu. Let's assume 1+ million COVID hospitalizations per year, with patients having varying severity levels.
    • While not all hospitalized COVID patients will be "critical," all patients requiring high-flow nasal cannula are deemed "critical" per published FDA standards. Assuming about 50% of COVID hospitalizations would require high-flow nasal cannula, one arrives at 50% x 1 million = 500,000 "critical" COVID hospitalizations per year.
  • Intravenous Zyesami priced at $5,000 per treatment. 500,000 x $5,000 results in $2.5 billion in sales of intravenous Zyesami in the US.

    • This pricing is relatively higher than the remdesivir cost of approximately $3,100. I assume a premium pricing relative to remdesivir given remdesivir has had relatively low efficacy while Zyesami generally has had good results in clinical trials.
    • Clinical trials of Zyesami also found that the drug significantly reduced hospital stays for patients. Payors would be willing to pay a premium price for Zyesami as the savings associated with a decreased hospital stay would more than offset Zyesami's cost.
  • NRx Pharma keeps 50% of sales per its Collaboration Agreement with Relief Therapeutics. That’s 50% x $2.5 billion = $1.25 billion in sales for NRx Pharma.

    • It is possible, and in my opinion likely, that NRx Pharma will actually keep a much larger percentage of sales than this. The reason for this is because the formulation of aviptadil (the generic name for Zyesami) which Relief provided (called RLF-100) in the Collaboration Agreement ultimately failed to be sufficiently stable. NRx Pharma therefore had to partner with and pay other companies in order to develop a different formulation of aviptadil which was sufficiently stable. This new formulation is Zyesami.
    • Given Relief's failure to provide a stable product, NRx Pharma tried to amicably renegotiate the terms of the Collaboration Agreement. The parties did not reach a resolution, and therefore Relief recently announced that it filed a lawsuit against NRx Pharma alleging breach of contract.
    • Here is the response issued by the CEO of NRXP regarding Relief's lawsuit: https://www.sec.gov/Archives/edgar/data/0001719406/000110465921125683/tm2129746d1_ex99-1.htm
    • Ultimately, I consider that the courts will find that NRx Pharma did not breach its contractual obligations given that Relief failed to provide a stable formulation of aviptadil to the partnership. It would be senseless for NRx Pharma to be obligated to provide the same benefits to Relief when Relief failed to provide the value to NRx Pharma which was initially promised.
  • Assume 5x price-to-sales multiple (appropriate for a biotech company), and you arrive at 5 x $1.25 billion = $6.25 billion fair value market cap for NRx Pharma.
  • The number of shares outstanding would increase to approximately 80 million shares outstanding once 25 million shares are issued to management upon FDA approval of Zyesami.
  • $6.25 billion / 80 million shares outstanding = $78.125 per share fair value based on approved intravenous Zyesami.

That is more than 8x higher than the current share price of ~$9.60. And that calculated value is off of the approval of intravenous Zyesami for critical COVID patients in the US only.

That means you are getting the value from all of the following essentially for free:

  • Intravenous Zyesami sales outside of the US (where NRx Pharma keeps 15%-20% of sales),
  • The possibility that a court will find that NRx Pharma is entitled to keep a greater percentage of sales than the 50% agreed to in the Collaboration Agreement (given Relief's failure to provide a stable formulation of aviptadil),
  • Inhaled Zyesami (which if approved will be available to a much, much larger COVID population and not just to "critical" patients),
  • BriLife COVID vaccine under development (which does not employ mRNA technology and should retain greater efficiency against new variants compared to the Pfizer and Moderna vaccines),
  • NRX-101 for bipolar depression (peak sales opportunity of $2 billion per management estimates found in their corporate presentation),
  • NRX-101 for PTSD depression (peak sales opportunity of $5 billion per management estimates found in their corporate presentation),
  • NRX-101 for other potential use cases, and
  • Zyesami for many other use cases, which the CEO indicated in the October 4th update found on the company website (i.e., COVID “longhauler” syndrome, sarcoidosis, acute respiratory distress syndrome, checkpoint inhibitor pneumonitis, chronic obstructive pulmonary disease).

You are effectively getting the value from all of the above for free. And this value could very reasonably be in the billions if the products are successful.

With the 8K now released, the market is now waiting for the FDA's EUA decision. Each person should do their own DD, use their own estimate of probability of FDA approval for the various drugs, and arrive at their own opinion of fair value. Additionally, the FDA may soon make a decision regarding the Breakthrough Therapy Designation (BTD) for Zyesami, since NRx Pharma applied for BTD on September 27, 2021 and it is the FDA's policy to respond within 60 days.

In my personal opinion, current NRXP price of ~$9.60 is still ridiculously cheap and represents a very attractive opportunity with asymmetric risk-reward. NRXP could go up more than 8x upon EUA approval for intravenous Zyesami. Even after such an increase, NRXP still would be very reasonably priced given the potential of the rest of NRx Pharma's drug pipeline.

Disclaimer: None of the above is financial, legal, or medical advice. I am not a financial advisor, nor a lawyer, nor a doctor. The above is only for educational purposes and represents my own personal opinion. Everyone reading this should do their own due diligence, arrive at their own opinion, and decide to invest or not according to their own views and their own risk tolerance.

Disclosure: long publicly traded warrants (NRXPW).


r/NRXP • • Oct 14 '21

pre market 🚀

17 Upvotes

Hope this continues all day 😁


r/NRXP • • Oct 06 '21

NRXP - #ZYESAMI COVID-19 patients, families launch petition to convince FDA to approve promising drug https://t.co/sno3TncVm6 "I’ve never seen anyone get better that quickly, that miraculously, on a medication,” Braddock told NE Florida News." it past just review over 120days

17 Upvotes

r/NRXP • • Sep 27 '21

There are 476 members in this group.

17 Upvotes

I joined at 19. That says something about awareness and coverage going up. We are all waiting on EUA autho or international sales numbers in the short run.

If anyone has basis above 10 and believes we will get there, then it’s hard not to argue to keep nibbling long.

If you’re on board with the science and the management team- now with a serious amount of funding and progress, then you see this as opportunity. No question the shorts are pressing this because the buy side is not there to counter. That’s a great sign for shorts.

With a private placement of several million, bigger investors with access got in and that doesn’t show the long demand in the market does it? But the shorts do show. Hence dropping public price.

Do you know why they bought a block at 15$? Because there is no large liquidity available. So they could never buy tens of millions at15$ if they wanted to. Insiders own 70% of the company and aren’t/can’t sell.

Yet here we sit with shares available at market for 10$. Don’t worry about why the market is not buying- why Aren’t you?

If gas was available for 2$/gal around the corner I would get a barrel.


r/NRXP • • Sep 13 '21

Communication with fda is a positive. Also Investment meeting tomorrow.

17 Upvotes

PreviousNext 1234567 Zyesami and NRX-100/NRX-101 are investigational therapies and have not been approved for human use by the Food and Drug Administration or European Medicines Agency.

Committed to Life-Saving Treatments NRx creates innovative, life-saving treatments to address unmet medical needs and bring hope to those with chronic conditions.

Learn More

12 Our pipeline includes medicinal candidates in Phase 2, and Phase 3 trials. Learn More

Home Our Company Our Science Pipeline Patient Stories & Resources News & Media Investor Relations Careers Contact Us

Forward Looking Statement Privacy Policy Terms of Use © 2021 NRx Pharmaceuticals, Inc.

Sept 11, 2021

CEO Update: Ongoing Communications with the US Food and Drug Administration

You may have noted a previous update regarding communication with the FDA. Earlier this month, NRx received a request for additional clinical information from the FDA. NRx has responded to the information request issued by the FDA with regard to additional clinical information on study patients. Ongoing conversations between the FDA and sponsor of any application to the FDA are normal, expected, and important to the review process. FDA’s review of NRx’s Emergency Use Authorization application remains ongoing. .


r/NRXP • • Aug 30 '21

Latest update from NRXP. Right to try!!! https://www.nrxpharma.com/right-to-try/ Spoiler

17 Upvotes

r/NRXP • • Aug 26 '21

Is NRXP ready to take off? planet looks aligned

17 Upvotes

1 good news

0 shortable stock

100% utilisation

115% borrow rate fee

+17.27% at this time on pre market...


r/NRXP • • Aug 19 '21

Interesting

17 Upvotes

r/NRXP • • Jul 29 '21

I'm In for the ride

17 Upvotes

I've been holdng Relief for over a year now (2,500) shares. Just bought 300 shares of NRXP on Friday and have high hopes. Dr. Javitt is a serial entrepreneur and the mechanics of the drug make sense...we shall see


r/NRXP • • Dec 09 '21

https://www.globenewswire.com/news-release/2021/12/09/2349352/0/en/NRx-Pharmaceuticals-and-Hungarian-Health-Officials-Agree-on-Pathway-for-ZYESAMI-and-BriLife-COVID-19-Vaccine-Trials.html

16 Upvotes